Cannabis Bioscience Delays Quarterly SEC Filing

Cannabis Bioscience International Holdings ( (CBIH) ) has released a notification of late filing.

Cannabis Bioscience International Holdings, Inc. has notified regulators that it will be late filing its Form 10-Q (Quarter Report) for the quarter ended February 28, 2026, via a Form 12b-25. The company says the financial information for the Form 10-Q (Quarter Report) for the quarter ended February 28, 2025, could not be analyzed and completed in time.

The delay is attributed broadly to the time and effort required to finalize the quarterly financial data, which management states could not be completed without unreasonable effort or expense. No specific issues such as auditor changes or internal control failures were disclosed in the notification.

Cannabis Bioscience International Holdings expects to file the delayed Form 10-Q (Quarter Report) within the standard grace period allowed under SEC Rule 12b-25. For a quarterly report, this means management plans to submit the filing within five calendar days after the original due date.

Preliminary numbers suggest a narrower operating loss and tighter cost structure, but weaker top-line performance. For the three months ended February 28, 2026, the company projects an operating loss of about $82,000 versus $129,234 a year earlier, with revenues of roughly $11,000 and gross profit of $8,000 compared with $14,931 and a gross loss of $4,465 in the prior-year quarter.

For the nine months ended February 28, 2026, the operating loss is estimated at approximately $252,000, slightly improved from $286,465 for the prior-year period. Revenues and gross profit for the nine months are expected to be about $89,000 and $67,000, down sharply from $268,066 and $232,505, respectively, as the company also reports materially lower operating expenses.

Operating expenses for the latest quarter are projected at around $90,000, compared with $124,769 a year earlier, driven mainly by lower general and administrative costs and reduced contract labor, partly offset by higher professional fees and rent. For the nine-month period, operating expenses are estimated at about $319,000, down from $518,970, reflecting broad cost cuts, with a modest increase in officer compensation.

These figures are preliminary and forward-looking, and actual results may differ once the Form 10-Q (Quarter Report) is filed and reviewed in full context. Investors should treat these estimates as indicative rather than final and remain alert to any revisions or additional disclosures in the forthcoming quarterly filing.

The company indicates that all other required periodic reports over the past 12 months have been filed, signaling ongoing baseline compliance with reporting obligations. The notification was signed on April 14, 2026, by Chief Executive Officer Dante Picazo, who also serves as principal accounting officer, underscoring executive responsibility for completing the delayed quarter report.

More about Cannabis Bioscience International Holdings

Current Market Cap: $4.65M

Find detailed analytics on CBIH stock on TipRanks’ Stock Analysis page.